RAC 2.92% $1.94 race oncology ltd

Ann: Positive Pre-IND Guidance from FDA on Zantrene, page-55

  1. 2,658 Posts.
    lightbulb Created with Sketch. 2792
    yep that is a benefit, and get greater market exposure.

    Was also thinking IND approval for AML target will pave the way for Cardio protect trial.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.